Johnson & Johnson News - August 21, 2026

Farallon Capital more than doubles its Johnson & Johnson stake

Farallon Capital Management significantly increased its stake in Johnson & Johnson by over 175%, bringing its total holdings to 408,000 shares. According to...

Johnson & Johnson Secures EU Approval for TECVAYLI, Targeting Second-Line Myeloma

The European Commission approved an expanded indication for Johnson & Johnson’s TECVAYLI (teclistamab) in combination with daratumumab. This treatment targets...